Fig. 6: Ad[CE1A] in combination with different classes of anti-myeloma drugs results in enhanced cell death.
From: An oncolytic adenovirus targeting SLAMF7 demonstrates anti-myeloma efficacy
Cell viability of Ad[CE1A] ± (a.i) bortezomib, (b.i) melphalan, (c.i) panobinostat or (d.i) pomalidomide combinations vs. monotherapies in 5TGM1 cells using AlamarBlue®. n = 5 biological replicates ±SD. p values: 2-way ANOVA Tukey’s correction. Heatmap of combination index (CI) of Ad[CE1A] in combination with (a.ii) bortezomib, (b.ii) melphalan, (c.ii) panobinostat or (d.ii) pomalidomide in human (JJN-3, U266, OPM-2) and murine (5TGM1) myeloma cell lines. For bortezomib on the y axis two doses are denoted, the first dose was used for the human myeloma cells and the second for the murine 5TGM1 cells. CI was determined by Compusyn. <0·3 strong synergism; 0·3-0·7 synergism; 0·7-0·9 moderate synergism; 0·9–1·1 additive; 1·1–1·45 slight antagonism; 1·45–2 antagonism.
